Are low doses of antipsychotics effective in the management of psychomotor agitation? a randomized, rated-blind trial of 4 intramuscular interventions

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 306-312

  Mantovani, Celia ^a   Labate, Cybelli Morello ^a   Sponholz, Alcion ^a   De Azevedo Marques, João Mazzoncini ^a   Guapo, Vinicius Guandalini ^a   De Simone Brito Dos Santos, Maria Eugênia ^a   Pazin Filho, Antonio ^b   Del Ben, Cristina Marta ^a  

^a Department of Neurosciences and Behavior   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

acute agitation management; aggression; management of aggression; psychomotor agitation; violent patient

Indexed keywords

HALOPERIDOL; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; ZIPRASIDONE;

ADULT; AGITATION CALMNESS EVALUATING SCALE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; UGVALG KLINISK UNDERSGELSER SIDE EFFECT SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; PSYCHOMOTOR AGITATION; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877575553     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182900fd6     Document Type: Article

References (24)

1. Canas F. Management of agitation in the acute psychotic patientYefficacy without excessive sedation. Eur Neuropsychopharmacol. 2007; 17(suppl 2): S108YS114.
2. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003; 20(4): 339-346.
3. Vass A. NICE guidance a real victory for people with schizophrenia. National Institute for Clinical Excellence. BMJ. 2002; 324(7351): 1413.
4. Zimbroff DL. Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs. 2008; 22(3): 199-212.
5. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997; 15(4): 335-340.
6. Bieniek SA, Ownby RL, Penalver A, et al. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy. 1998; 18(1): 57-62.
7. Castle DJ, Udristoiu T, Kim CY, et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry. 2009; 10(1): 43-53.
8. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006; 188(3): 281-292.
9. Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005; 12(12): 1167-1172.
10. Huf G, Coutinho ES, Adams CE,, TREC Collaborative Group. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ. 2007; 335(7625): 869.
11. Alexander J, Tharyan P, Adams C, et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry. 2004; 185: 63-69.
12. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005; 11(suppl 1): 5-108; quiz 10-12.
13. McAllister-Williams RH, Ferrier IN. Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry. 2002; 180: 485-489.
14. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002; 26(4): 494-504.
15. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276.
16. Chaves AC, Shirakawa I. Escala das s?ndromes negativa e positivaVPANSS e seu uso no Brasil. Rev Psiquiatr Clin. 1998; 25(6): 337-343.
17. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987; 334: 1-100.
18. Del-Ben CM, Hallak JE, Sponholz A Jr, et al. Accuracy of psychiatric diagnosis performed under indirect supervision. Rev Bras Psiquiatr. 2005; 27(1): 58-62.
19. Wyant M, Diamond BI, O'Neal E, et al. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull. 1990; 26(1): 126-129.
20. Nobay F, Simon BC, Levitt MA, et al. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med. 2004; 11(7): 744-749.
21. Baldacara L, Sanches M, Cordeiro DC, et al. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Rev Bras Psiquiatr. 2011; 33(1): 30-39.
22. Suzuki A, Yasui-Furukori N, Mihara K, et al. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003; 25(2): 192-196.
23. Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J. 1999; 92(10): 1017-1018.
24. Mendhekar DN, Andrade CR. Neuroleptic malignant syndrome with promethazine. Aust N Z J Psychiatry. 2005; 39(4): 310.